Introduction
One in six men will develop prostate cancer in their lifetime [1] . The most consistent risk factors for the development of prostate cancer are advancing age, family history and race [2] . Interestingly, men in South East Asian countries have a lower incidence of prostate cancer that increases rapidly after immigration to the West suggesting that the pathogenesis of prostate cancer reflects both hereditary and environmental components [2] . It has been suggested that chronic inflammation might be important in prostate carcinogenesis. Transitions between areas of PIA and high grade prostatic intraepithelial neoplasia and adenocarcinoma have been observed [2] . Furthermore, PIA lesions may be a manifestation of the 'field effect' caused by environmental exposures [2] . In fact, prostate cancer is histologically heterogeneous and multifocal in as many as 85% of patients [3] .
Clinical screening of the prostate is performed with digital rectal examination (DRE) and serum prostate specific antigen (PSA) measurement. DRE has a low sensitivity in the detection of prostate cancer while elevated PSA has a high sensitivity but low specificity in the detection of cancer with elevated levels seen in the presence of prostatitis, benign prostate hypertrophy (BPH) and post-instrumentation [4] . Positive predictive values for the detection of early prostate cancer have been reported as 21% for DRE and 32% for PSA [4] . In patients with abnormal DRE or elevated PSA, transrectal ultrasound (TRUS) guided biopsies are performed for histoligical diagnosis and to determine Gleason grade which is an indicator of tumour aggressiveness. These systematic random biopsies are prone to undersampling with 35% of cancers missed on first biopsy [5] and underestimation of Gleason grade in 46% of cases [6] .
Hence, multi-parametric magnetic resonance imaging Many prostate diseases have a zonal distribution, for example 70% of adenocarcinomas arise in the PZ, with 20% in the TZ and 10% in the CZ [3] ; BPH usually involves the TZ [3] . 
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The European Society of Urogenital Radiology (ESUR) published guidelines for prostate imaging in 2012 [10] .
The guidelines recommend three MRI scanning protocols for tumour detection, local staging and node and bone metastases evaluation. The ESUR propose a PI-RADS scoring system which relays the probability of a lesion being a clinically significant cancer. The scoring criteria include T2WI for the PZ and TZ, DWI, DCE-MRI and extra-prostatic disease. MRSI is given as an optional technique. A 5 point scale is allocated for each imaging sequence with a score of 1 indicating that clinically significant cancer is highly unlikely to be present and a score of 5 indicating that clinically significant cancer is highly likely to be present. Each lesion is then given an overall score to predict its chance of being a clinically significant cancer.
On T2WI, a round or ill-defined homogeneously hypointense focus in the PZ is suspicious for cancer.
Bulging of the capsule, broad contact of more than 1.5cm with the capsule or extracapsular extension increases likelihood of malignancy [10] (Figure 1) . A linear, wedge shaped or geographic area of hypointensity in the PZ which is usually not well demarcated is more likely to represent a benign process [10] . This may be seen in cases of prostatitis, atrophy, A time interval of 4-6 weeks between biopsy and MRI has been recommended [13] , however if significant haemorrhage is still seen, postponing the study for a further 3-4 weeks to allow resolution of the haemorrhage is recommended [10] .
Extracapsular extension of tumour is best evaluated on T2WI. Capsular breach by tumour may manifest as tumour abutment, bulging, loss of definition and irregularity of the prostate capsule [10] . Thickening of the neurovascular bundle, measurable extra-capsular disease and obliteration of the recto-prostatic angle may be evident [10] . Seminal vesicle infiltration may manifest as expansion, hypointensity on T2WI, filling in of the prostate-seminal vesicle angle, abnormal enhancement and restricted diffusion [10] . Tumour adjacent to the bladder neck, loss of low T2W signal of the bladder muscle and abnormal enhancement extending into the bladder neck is indicative of bladder On MRSI, the relevant metabolites are citrate which is a marker of benign tissue, creatine which is insignificant for diagnosis but difficult to resolve from choline and choline which is a marker of malignancy. In quantitative analysis, a choline-plus-creatine-to-citrate (CC/C) ratio is estimated, with ratios of >0.86 in the PZ and >0.94 in the central gland indicative of malignancy [10] . In qualitative analysis the peak heights of citrate and choline are visually compared. A choline peak height exceeding a citrate peak height by >1 times is likely to represent clinically significant cancer [10] .
Conclusion
Clinical screening for prostate cancer with DRE and PSA measurements has its limitations. Random TRUSguided biopsies may miss cancers and may 
